Using Targeted Virotherapy to Treat a Resistant Ewing Sarcoma Model: From the Bedside to the Bench and Back
Figure 1
VSVΔM51 infects primary human Ewing sarcoma specimen obtained from the proximal humerus lesion. The tumor specimen was inoculated with 1 × 106 pfu/mL of VSVΔM51-GFP. GFP expression was monitored using a fluorescent microscope 24 hrs after inoculation and the green fluorescence represents infected cells. Normal adjacent muscle control tissue is resistant to infection.
